NewsBenzingaNovo Nordisk Submits FDA New Drug Application And EMA Marketing Authorization Application For Etavopivat For Treatment Of Adolescents And Adults With Sickle Cell Disease Novo Nordisk Submits FDA New Drug Application And EMA Marketing Authorization Application For Etavopivat For Treatment Of Adolescents And Adults With Sickle Cell Disease Benzinga 2026.11.13 11:05 (GMT+0) Open on Benzinga Other news APT Drops 24% in a Week, Erasing Its Autumn Rally Doubao Work: Daily Active Users Top 8 Million, Enterprise Client ARR Exceeds 2 Billion Yuan Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition Dear Nvidia Stock Fans, Mark Your Calendars for December 10 Nvidia clarifies when it will — and won’t —keep financing neoclouds Global-E Online Stock Is Falling Wednesday: What's Going On?
Rantizo (Nasdaq: RNTZ) Issues Letter to Shareholders Outlining Revenue-Focused American Drone Strategy After $258.8 Million Acquisition